Elutia Inc. (ELUT)

NASDAQ: ELUT · Real-Time Price · USD
1.930
-0.110 (-5.39%)
At close: May 5, 2025, 4:00 PM
2.000
+0.070 (3.63%)
After-hours: May 5, 2025, 7:10 PM EDT
-5.39%
Market Cap 78.62M
Revenue (ttm) 24.38M
Net Income (ttm) -53.95M
Shares Out 40.74M
EPS (ttm) -1.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 51,085
Open 2.100
Previous Close 2.040
Day's Range 1.930 - 2.100
52-Week Range 1.870 - 5.240
Beta 0.97
Analysts Strong Buy
Price Target 9.00 (+366.32%)
Earnings Date May 8, 2025

About ELUT

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women’s Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides Prox... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Oct 8, 2020
Employees 51
Stock Exchange NASDAQ
Ticker Symbol ELUT
Full Company Profile

Financial Performance

In 2024, Elutia's revenue was $24.38 million, a decrease of -1.50% compared to the previous year's $24.75 million. Losses were -$53.95 million, 43.3% more than in 2023.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ELUT stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 366.32% from the latest price.

Price Target
$9.0
(366.32% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-...

4 days ago - GlobeNewsWire

Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its ...

4 days ago - GlobeNewsWire

Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29

SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., El...

13 days ago - GlobeNewsWire

Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

— Integration of clinical and patient-reported outcomes expected to further differentiate EluPro's utility in cardiac implantable electronic device (CIED) procedures — SILVER SPRING, Md., April 21, 20...

14 days ago - GlobeNewsWire

Elutia Confirms No Material Impact from Global Tariffs

SILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today confirmed that the ongoing global tar...

21 days ago - GlobeNewsWire

Elutia to Participate in Upcoming Investor Conferences

SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chie...

4 weeks ago - GlobeNewsWire

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025 SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in ...

4 weeks ago - GlobeNewsWire

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Seventh GPO Agreement Signed Since EluPro's Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix pr...

5 weeks ago - GlobeNewsWire

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

— Rigorous testing demonstrates robust antimicrobial performance against bacterial strains relevant to cardiac implanted electronic device (CIED) infections — SILVER SPRING, Md., March 25, 2025 (GLOBE...

5 weeks ago - GlobeNewsWire

Elutia Inc. (ELUT) Q4 2024 Earnings Call Transcript

Elutia Inc. (NASDAQ:ELUT) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants David Carey – FINN Partners C. Randal Mills – Chief Executive Officer Matt Ferguson – Chief Fi...

2 months ago - Seeking Alpha

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization – SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Eluti...

2 months ago - GlobeNewsWire

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its...

2 months ago - GlobeNewsWire

Elutia Announces $15.0 Million Registered Direct Offering

SILVER SPRING, Md., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase ...

3 months ago - GlobeNewsWire

Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript

Elutia Inc. (NASDAQ:ELUT) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Matt Steinberg – FINN Partners Randy Mills – Chief Executive Officer Matt Ferguson – Chief...

6 months ago - Seeking Alpha

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Exec...

6 months ago - GlobeNewsWire

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices

EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model

8 months ago - GlobeNewsWire

Elutia Celebrates First Year

Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in ...

8 months ago - GlobeNewsWire

Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever p...

8 months ago - GlobeNewsWire

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

9 months ago - GlobeNewsWire

Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript

Elutia Inc. (NASDAQ:ELUT) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners, IR Randy Mills - President and CEO Matt Ferguson - Chief Fina...

9 months ago - Seeking Alpha

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as...

9 months ago - GlobeNewsWire

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

SILVER SPRING, Md., July 11, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Exe...

10 months ago - GlobeNewsWire

Elutia Announces $13.26 Million Registered Direct Offering

SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase ...

11 months ago - GlobeNewsWire

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market

11 months ago - GlobeNewsWire

Elutia, Inc. (ELUT) Q1 2024 Earnings Call Transcript

Elutia, Inc. (NASDAQ:ELUT) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Randy Mills - President and Chief Executive Officer Matthew Ferg...

1 year ago - Seeking Alpha